Exposure–Response Modeling and Simulation of Progression‐Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer

Sorafenib is an oral multikinase inhibitor approved for the treatment of differentiated thyroid carcinoma (DTC), renal cell carcinoma, and hepatocellular carcinoma. In the phase III DECISION trial in patients with DTC, sorafenib exposure and the incidence of some adverse events (AEs) were higher tha...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Transl Sci
Main Authors: Grevel, Joachim, Jentsch, Garrit, Austin, Rupert, Prins, Nicolaas H., Lettieri, John, Mitchell, David, Huang, Funan, Brose, Marcia S., Schlumberger, Martin, Meinhardt, Gerold, Peña, Carol E. A., Ploeger, Bart A.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6742948/
https://ncbi.nlm.nih.gov/pubmed/30920122
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.12634
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados